Hovione Expands Particle Design Solutions to Solve Bioavailability and Other Drug Delivery Challenges
LOURES, Portugal, September 27, 2012 /PRNewswire/ –
Hovione today announced the expansion of its solutions to solve issues of poor
bioavailability, patient acceptability and the enabling of optimal delivery for non-oral
routes of administration.
Building on the experience of more than 100 projects and successful commercialization
of spray dried dispersions, Hovione’s toolkit of solutions now includes crystal design,
particle size reduction to the micro or nano-scale and amorphous solid dispersions. These
services are offered from bench to commercial scale and are complemented with formulation
development and clinical manufacture to Phase II.
“We are very pleased to offer our customers these technologies. In response to
customers’ needs, Hovione is investing in new technologies, many of them capable of
handling highly potent compounds. These will help drive compounds with development
challenges from early clinical to market,” said Guy Villax, Chief Executive.
Colin Minchom PhD, who has been leading Hovione’s Particle Design business since
March, stated: “More than the technologies, the quality of Hovione’s scientists, engineers
and their experience in the application of 21st Century methodologies such as QbD, PAT and
process modelling are outstanding.”
Hovione will be presenting its new offering in detail during the AAPS Annual Meeting
and Exposition at McCormick Place, Chicago USA. Hovione scientists and staff will be
available to support your queries at booth 3936 from October 15-17. The company will also
be exhibiting at Booth 3D39 at CPhI in Feria de Madrid, Spain (October 9-11). For those
that are interested in the offering but are not able to attend either event, please visit
hovione.com/pd [http://www.hovione.com/pd ] or contact email@example.com .
About Hovione. Hovione is a global company with over 50 years’ experience in Active
Pharmaceutical Ingredient and Drug Product Intermediate development and compliant
manufacture. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the
company focuses on the most demanding customers in the most regulated markets. Hovione
offers integrated API, particle design, formulation development and manufacturing. In the
inhalation area, Hovione is the only independent company offering such a broad range of
Hovione Marketing & Communication Tel: +351-21-982-9117 - Fax: +351-21-982-9118 Email: firstname.lastname@example.org